Bernadette Connaughton


Ms. Connaughton brings more than 30 years of global strategic, commercial and biopharmaceutical industry expertise. She spent her career at Bristol-Myers Squibb, building a consistent track record of achieving sales growth, improving profitability and transforming operational models. She most recently served as president Intercontinental, including China, Latin America, Central and Eastern Europe and Middle East. In this position, she developed the multi-year strategy for the successful commercialization of a number of oncology, virology and immunology products, including Opdivo®, Yervoy®, Sprycel®, Daklinza® and Orencia®. She has held other senior leadership positions at Bristol-Myers Squibb, including president, European Markets, Canada and Australia; president, Intercontinental; and president, Japan, Pacific Rim, Australia and Canada; senior vice president, Cardiovascular and Metabolic Business Unit, U.S.; and senior vice president, Primary Care Marketing, U.S. Ms. Connaughton was a member of the board of directors of Visterra, Inc., a private clinical stage biotechnology company recently acquired by Otsuka. Ms. Connaughton currently serves on the board of directors of Zealand Pharma A/S, Editas Medicine, Inc. and Syneos Health, Inc. She also previously served on the European Federation of Pharmaceutical Industry Association, Patient Access and European Markets Committees. She received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania. Ms. Connaughton is the Chair of the Compensation Committee.